Genetic polymorphisms of LMP/TAP gene and hepatitis B virus infection risk in the Chinese population

Journal of Clinical Immunology

Volumn 27, Issue 5, 2007, Pages 534-541

  Xu, Changqing ^a   Qi, Suxia ^b   Gao, Lei ^c   Cui, Hong ^c   Liu, Meiqiang ^a   Yang, Hongli ^a   Li, Kun ^a   Cao, Bangwei ^c  

^a THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b QINGDAO MUNICIPAL HOSPITAL   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Hepatitis B virus (HBV); LMP TAP; Polymorphism

Indexed keywords

ADULT; ANTIGEN PRESENTATION; ARTICLE; CHINESE; CODON; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE FREQUENCY; GENE LOCUS; GENETIC POLYMORPHISM; HAPLOTYPE; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; INFECTION RISK; INFECTION SENSITIVITY; LMP GENE; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TAP GENE; VIRUS INFECTION;

ADULT; ATP-BINDING CASSETTE TRANSPORTERS; CASE-CONTROL STUDIES; CHINA; DIMERIZATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MALE; POLYMORPHISM, GENETIC; PROTEIN SUBUNITS; RISK ASSESSMENT;

EID: 34548207774     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-007-9095-x     Document Type: Article

References (37)

1. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M: Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 77:801-807, 1999
2. Lok AS: Chronic hepatitis B. N Engl J Med 346:1682-1683, 2002
3. Wang FS: Current status and prospects of studies on human genetic alleles associated with hepatitis B virus infection. World J Gastroenterol 9:641-644, 2003
4. Chironna M, Germinario C, Lopalco PL, Quarto M, Barbuti S: HBV, HCV and HDV infections in Albanian refugees in Southern Italy (Apulia region). Epidemiol Infect 125:163-167, 2000
5. Pokorski RJ, Ohlmer U: Long-term morbidity and mortality in Chinese insurance applicants infected with the hepatitis B virus. J Insur Med 33:143-164, 2001
6. Lemon SM, Layden TJ, Seeff L, et al.: The 20th United States-Japan joint hepatitis panel meeting. Hepatology 31:800-806, 2000
7. Rehermann B, Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol l5:215-229, 2005
8. Hatzakis A, Magiorkinis E, Haida C: HBV virological assessment. J Hepatol 44(suppl):s71-s76, 2006
9. York IA, Rock KL: Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14:369-396, 1996
10. Rechsteiner M, Hill CP: Mobilizing the proteolytic machine: Cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 15:27-33, 2005
11. Kelly A, Powis SH, Kerr LA, et al.: Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. Nature 355:641-644, 1992
12. Kloetzel PM, Ossendorp F: Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 16:76-81, 2004
13. Jung MC, Pape GR: Immunology of hepatitis B infection. Lancet Infect Dis 2:43-50, 2002
14. Vargas-Alarcon G, Gamboa R, Zuniga J, et al.: Association study of LMP gene polymorphisms in Mexican patients with spondyloarthritis. Hum Immunol 65:1437-1442, 2004
15. Prahalad S, Kingsbury DJ, Griffin TA, et al.: Polymorphism in the MHC-encoded LMP7 gene: Association with JRA without functional significance for immunoproteasome assembly. J Rheumatol 28:2320-2325, 2001
16. McTernan CL, Stewart LC, Mijovic CH, Barnett AH: Assessment of the non-HLA-DR-DQ contribution to IDDM1 in British Caucasian families: Analysis of LMP7 polymorphisms. Diabet Med 17:661-666, 2000
17. Cao B, Tian X, Li Y, et al.: LMP7/TAP2 gene polymorphisms and HPV infection in esophageal carcinoma patients from a high incidence area in China. Carcinogenesis 26:1280-1284, 2005
18. Khu YL, Tan YJ, Lim SG, Hong W, Goh PY: Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity. Biochem J 384:401-409, 2004
19. Lautscham G, Rickinson A, Blake N: TAP-independent antigen presentation on MHC class I molecules: lessons from Epstein-Barr virus. Microbes Infect 5:291-299, 2003
20. Neumeister C, Nanan R, Cornu T, et al.: Measles virus and canine distemper virus target proteins into a TAP-independent MHC class I-restricted antigen-processing pathway. J Gen Virol 82:441-447, 2001
21. Taniuchi S, Masuda M, Teraguchi M, et al.: Polymorphism of Fcgamma RIIa may affect the efficacy of gamma-globulin therapy in Kawasaki disease. J Clin Immunol 25:309-313, 2005
22. van Belzen MJ, Mulder CJ, Zhernakova A, Pearson PL, Houwen RH, Wijmenga C: CTLA4 +49A/G and CT60 polymorphisms in Dutch coeliac disease patients. Eur J Hum Genet 12:782-785, 2004
23. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989, 2001
24. Tang J, Freedman DO, Allen S, et al.: Genotyping TAP2 variants in North American Caucasians, Brazilians, and Africans. Genes Immun 2:32-40, 2001
25. Drysdale CM, McGraw DW, Stack CB, et al.: Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 97:10483-10488, 2000
26. Rehermann B, Lau D, Hoofnagle JH, Chisari FV: Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 97:1655-1665, 1996
27. Wieland SF, Vega RG, Muller R, et al.: Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol 77:1227-1236, 2003
28. Robek MD, Boyd BS, Wieland SF, Chisari FV: Signal transduction pathways that inhibit hepatitis B virus replication. Proc Natl Acad Sci USA 101:1743-1747, 2004
29. Sijts AJ, Ruppert T, Rehermann B, Schmidt M, Koszinowski U, Kloetzel PM: Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. J Exp Med 191:503-514, 2000
30. Lee HJ, Ha SJ, Han H, Kim JW: Distribution of HLA-A, B alleles and polymorphisms of TAP and LMP genes in Korean patients with atopic dermatitis. Clin Exp Allergy 31:1867-1874, 2001
31. Dosenko VE, Mikhal'chuk D, Zagorii VIu, Parkhomenko AN, Moibenko AA: The frequency of allelic polymorphism of genes encoding immunoproteasome catalytic subunits in acute coronary syndrome patients. Tsitol Genet 39:50-54, 2005
32. Undlien DE, Akselsen HE, Joner G, et al.: No independent associations of LMP2 and LMP7 polymorphisms with susceptibility to develop IDDM. Diabetes 46:307-312, 1997
33. Androlewicz MJ, Ortmann B, van Endert PM, Spies T, Cresswell P: Characteristics of peptide and major histocompatibility complex class I/beta 2-microglobulin binding to the transporters associated with antigen processing (TAP1 and TAP2). Proc Natl Acad Sci USA 91:12716-12720, 1994
34. Holland IB, Blight MA: ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans. J Mol Biol 293:381-399, 1999
35. Knittler MR, Alberts P, Deverson EV, Howard JC: Nucleotide binding by TAP mediates association with peptide and release of assembled MHC class I molecules. Curr Biol 9:999-1008, 1999
36. Lapinski PE, Neubig RR, Raghavan MW: A lysine mutations of TAP1 and TAP2 interfere with peptide translocation but not peptide binding. J Biol Chem 76:7526-7533, 2001
37. Alberts P, Daumke O, Deverson EV, Howard JC, Knittler MR: Distinct functional properties of the TAP subunits coordinate the nucleotide-dependent transport cycle. Curr Biol 11:242-251, 2001